Vivos Therapeutics Inc (VVOS) Stock Price, Quote & News

Company Profile

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children....

Industry: Medical Devices

Sector: Healthcare

Phone: 844 672 4357

Website: www.vivos.com

Address:

7921 Southpark Plaza, Suite 210, Littleton, United States

Giovannirs3 Feb. 3 at 11:36 PM

$VVOS ➖️💯❤️🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤗🤗🤗🤗🤗👌👌

0 · Reply

IMGroot Feb. 3 at 11:03 PM

$VVOS waiting for rollover check to clear and I’m in for another 10k. I doubt we will be cash flow positive next ER but this is getting insanely priced.

1 · Reply

Giovannirs3 Feb. 3 at 9:01 PM

$VVOS 👇👍

0 · Reply

Are_You_Experienced Feb. 3 at 8:26 PM

$VVOS Shorts are covering

1 · Reply

Giovannirs3 Feb. 3 at 6:31 PM

$VVOS 🤣🤣🤣👇👇👇

0 · Reply

hectorgr Feb. 3 at 6:17 PM

$VVOS Its a permanent failure

0 · Reply

Giovannirs3 Feb. 3 at 6:14 PM

$VVOS ➖️💯❤️

0 · Reply

Giovannirs3 Feb. 3 at 6:13 PM

$VVOS 🤣🤣🤣🤣

0 · Reply

Are_You_Experienced Feb. 3 at 5:54 PM

$VVOS It is down 40% from the 2.5 recent high

1 · Reply

golfguy42360 Feb. 3 at 5:53 PM

$VVOS Don't see me getting my money back on this one.

0 · Reply

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

CERT ZLAB

Jan 20, 2026, 5:31 PM EST - 14 days ago

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

Jan 16, 2026, 8:00 AM EST - 18 days ago

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

Dec 16, 2025, 4:29 PM EST - 7 weeks ago

Vivos Therapeutics, Inc. (VVOS) Discusses Strategic Business Model Pivot and Transition in Sleep Apnea Treatment Approach Transcript

Dec 16, 2025, 8:45 AM EST - 7 weeks ago

Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan

Nov 19, 2025, 8:33 PM EST - 2 months ago

Vivos Therapeutics, Inc. (VVOS) Q3 2025 Earnings Call Transcript

Nov 19, 2025, 4:20 PM EST - 2 months ago

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

Nov 19, 2025, 8:30 AM EST - 2 months ago

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

Nov 4, 2025, 1:36 PM EST - 3 months ago

Vivos Therapeutics, Inc. (VVOS) Shareholder/Analyst Call Prepared Remarks Transcript

Sep 30, 2025, 8:30 AM EDT - 4 months ago

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

Sep 17, 2025, 8:30 AM EDT - 4 months ago

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

Aug 22, 2025, 3:08 PM EDT - 5 months ago

Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 4:20 PM EDT - 6 months ago

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 19, 2025, 8:30 AM EDT - 6 months ago

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

Jun 26, 2025, 8:30 AM EDT - 7 months ago

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

May 15, 2025, 7:31 PM EDT - 9 months ago

Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:15 AM EDT - 9 months ago

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

Apr 16, 2025, 8:30 AM EDT - 10 months ago

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

Apr 1, 2025, 12:18 AM EDT - 11 months ago

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:20 PM EDT - 11 months ago

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Mar 28, 2025, 8:30 AM EDT - 11 months ago

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Dec 23, 2024, 8:00 AM EST - 1 year ago

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 14, 2024, 11:31 PM EST - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 5:00 PM EST - 1 year ago

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Sep 18, 2024, 7:00 AM EDT - 1 year ago

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Aug 15, 2024, 2:05 PM EDT - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Jun 27, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

May 17, 2024, 9:02 PM EDT - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

May 14, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Mar 28, 2024, 11:10 PM EDT - 2 years ago

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Mar 28, 2024, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Feb 6, 2024, 7:30 AM EST - 2 years ago

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Jan 8, 2024, 7:30 AM EST - 2 years ago

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Dec 11, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Nov 29, 2023, 11:09 AM EST - 2 years ago

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

Nov 29, 2023, 7:44 AM EST - 2 years ago

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Nov 29, 2023, 7:30 AM EST - 2 years ago

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Nov 17, 2023, 7:12 PM EST - 2 years ago

Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 2 years ago

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Closes $4 Million Private Placement

Oct 26, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Reverse Stock Split

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Giovannirs3 Feb. 3 at 11:36 PM

$VVOS ➖️💯❤️🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤗🤗🤗🤗🤗👌👌

0 · Reply

IMGroot Feb. 3 at 11:03 PM

$VVOS waiting for rollover check to clear and I’m in for another 10k. I doubt we will be cash flow positive next ER but this is getting insanely priced.

1 · Reply

Giovannirs3 Feb. 3 at 9:01 PM

$VVOS 👇👍

0 · Reply

Are_You_Experienced Feb. 3 at 8:26 PM

$VVOS Shorts are covering

1 · Reply

Giovannirs3 Feb. 3 at 6:31 PM

$VVOS 🤣🤣🤣👇👇👇

0 · Reply

hectorgr Feb. 3 at 6:17 PM

$VVOS Its a permanent failure

0 · Reply

Giovannirs3 Feb. 3 at 6:14 PM

$VVOS ➖️💯❤️

0 · Reply

Giovannirs3 Feb. 3 at 6:13 PM

$VVOS 🤣🤣🤣🤣

0 · Reply

Are_You_Experienced Feb. 3 at 5:54 PM

$VVOS It is down 40% from the 2.5 recent high

1 · Reply

golfguy42360 Feb. 3 at 5:53 PM

$VVOS Don't see me getting my money back on this one.

0 · Reply

gforce77 Feb. 3 at 5:32 PM

$VVOS this stock has been frustrating for me, I love their situation but I just don't think they communicate PRs enough. This has become one of my largest positions yet it keeps reaching new lows. I am quite perplexed to say the least but I am not selling as I remember when this was in an uptrend and went up to nearly $8. Good luck to those in the same boat with me and frustrated but optimistic :)

4 · Reply

Moneyybaggs Feb. 3 at 5:32 PM

$VVOS Whatever that look is it ain’t good. Obviously Armistice is blowing out of their position as I predicted the morning after the company announced that Armistice had exercised their warrants at $2.34 and received new warrants. Their relentless selling is crushing the stock and Huntsman and the company do nothing to defend the stock. BUY SHARES ON THE OPEN MARKET HUNTSMAN!!! SHOW YOUR INVESTORS YOU BELIEVE IN YOUR COMPANY BY BUYING SHARES AT THIS ALL-TIME LOW!!!

1 · Reply

Tradelyfe Feb. 3 at 5:19 PM

$NUKK another one of AC investor blogger blah blah blah’s pics. Dude is a paid scammer… beware. He’s pushed this one, $LITM $PSQH $VVOS just to name a few. Awful awful human who shorts your buys. Please spread the word about this guy who hides out in Portugal

2 · Reply

Tradelyfe Feb. 3 at 5:12 PM

$LITM AC has been pushing this one…beware…look what’s become of $VVOS $PSQH and others. His only good call in 2 years was $GRRR , a lucky guess at that. He’s a paid pumper hired by failing companies. They’ll take your $

1 · Reply

fibtrader99 Feb. 3 at 4:55 PM

$VVOS stop selling at 1.50, you're messing up the chart

1 · Reply

Are_You_Experienced Feb. 3 at 4:45 PM

$VVOS I must admit that this share price, I am starting to lose confidence that this company will make it and most likely is going to be put up for sale. Huntsman has no idea how to stop the bleeding. no promotion at all

1 · Reply

kemsma62 Feb. 3 at 4:30 PM

$VVOS We need good news ASAP to hold $1 until next ER 😐🤞🤷‍♂️

1 · Reply

looop Feb. 3 at 4:20 PM

$VVOS bankruptcy 🔻🔻🔻

0 · Reply

looop Feb. 3 at 4:20 PM

$VVOS 🔻🔻🔻🔻🔻🔻🔻🔻🔻🔻

0 · Reply

Giovannirs3 Feb. 3 at 4:07 PM

$VVOS 👇

0 · Reply

Tradelyfe Feb. 3 at 3:46 PM

$VVOS never forget how much pumpkin AC did here and over at PSQH the last couple of years

0 · Reply

Tradelyfe Feb. 3 at 2:25 PM

$VVOS they going bankrupt? Huntsman is a joke. This shouldn’t be a publicly traded company. Most landscaping businesses have more revenue than these jokers

1 · Reply

Market Cap	15.29M
Revenue (ttm)	15.03M
Net Income (ttm)	-11.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-74.12%
Debt to Equity Ratio	3.45

Volume	174,700
Avg Vol	136,750
Day's Range	N/A - N/A
Shares Out	9.44M
Stochastic %K	13%
Beta	6.89
Analysts	Sell
Price Target	$5.00